Literature DB >> 12402162

Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP).

Mitsuhiro Osame1.   

Abstract

The recent studies have greatly improved our understanding of the pathological mechanisms of human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The pathological mechanisms of HAM/TSP based on the histopathological, immunological, and molecular analysis with emphasis on the longitudinal alterations of the disease will be discussed. Immunohistological examination revealed the existence and the activation both of HTLV-I-infected CD4+ cells and HTLV-I-specific CD8+ cytotoxic T lymphocytes in the spinal cord lesions, which suggest that they play an important role in the pathogenesis. Increased expression of several cytokines, Fas/Fas ligand, adhesion molecules, and molecules influencing T cell migration in the lesions have been reported. These cell infiltrates and cytokines they secrete in the lesions may damage bystander neural tissue. Furthermore, longitudinal alterations in the affected spinal cords suggest that the inflammatory process is gradually decreased. Epidemiological studies show that less than 5% of infected individuals develop HAM/TSP and indicate that increased proviral load of HTLV-I is a strong predictor for the development of HAM/TSP. A recent study has shown that the autoantibody for the ribonuclear protein-A1 can cross-react with HTLV-I Tax protein and inhibit neuronal firing ex vivo, indicating that a molecular mimicry of the humoral immune response may be involved in the pathogenesis of HAM/TSP. Based on these studies, two hypotheses can be proposed for the pathogenesis of HAM/TSP, where cellular and humoral immune responses both play important roles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12402162     DOI: 10.1080/13550280260422668

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  35 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

Review 2.  The immune response to HTLV-I.

Authors:  C R Bangham
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

3.  HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings.

Authors:  M Nakagawa; S Izumo; S Ijichi; H Kubota; K Arimura; M Kawabata; M Osame
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

4.  A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes.

Authors:  P Anderson; C Nagler-Anderson; C O'Brien; H Levine; S Watkins; H S Slayter; M L Blue; S F Schlossman
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

5.  HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.

Authors:  K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I.

Authors:  J E Kaplan; M Osame; H Kubota; A Igata; H Nishitani; Y Maeda; R F Khabbaz; R S Janssen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

7.  Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients.

Authors:  M Saito; N Nakamura; M Nagai; K Shirakawa; H Sato; N Kawahigashi; Y Furukawa; K Usuku; M Nakagawa; S Izumo; M Osame
Journal:  J Neuroimmunol       Date:  1999-08-03       Impact factor: 3.478

8.  CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I.

Authors:  M Nagai; M B Brennan; J A Sakai; C A Mora; S Jacobson
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

9.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

10.  Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization.

Authors:  T J Lehky; C H Fox; S Koenig; M C Levin; N Flerlage; S Izumo; E Sato; C S Raine; M Osame; S Jacobson
Journal:  Ann Neurol       Date:  1995-02       Impact factor: 10.422

View more
  32 in total

1.  High frequency of virus-specific CD8+ T cells in the central nervous system of macaques chronically infected with simian immunodeficiency virus SIVmac251.

Authors:  Marcin Moniuszko; Charlie Brown; Ranajit Pal; Elzbieta Tryniszewska; Wen-Po Tsai; Vanessa M Hirsch; Genoveffa Franchini
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals.

Authors:  T Luna; S B Santos; M Nascimento; M A F Porto; A L Muniz; E M Carvalho; A R Jesus
Journal:  Braz J Med Biol Res       Date:  2011-10-22       Impact factor: 2.590

3.  Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease.

Authors:  Sharrón L Manuel; Todd D Schell; Edward Acheampong; Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  J Leukoc Biol       Date:  2009-08-05       Impact factor: 4.962

4.  Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles.

Authors:  Vibeke Andresen; Cynthia A Pise-Masison; Uma Sinha-Datta; Marcia Bellon; Valerio Valeri; Robyn Washington Parks; Valentina Cecchinato; Risaku Fukumoto; Christophe Nicot; Genoveffa Franchini
Journal:  Blood       Date:  2011-06-15       Impact factor: 22.113

5.  Cross-reactive antibodies to target proteins are dependent upon oligomannose glycosylated epitopes in HTLV-1 associated neurological disease.

Authors:  Sangmin Lee; Yoojin Shin; Daniel Clark; Eduardo Gotuzzo; Michael C Levin
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

6.  Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease.

Authors:  Yoshihisa Yamano; Norihiro Takenouchi; Hong-Chuan Li; Utano Tomaru; Karen Yao; Christian W Grant; Dragan A Maric; Steven Jacobson
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

7.  Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder.

Authors:  Paulo Oliveira; Néviton M Castro; André L Muniz; Davi Tanajura; Julio C Brandão; Aurélia F Porto; Edgar M Carvalho
Journal:  Urology       Date:  2010-02-26       Impact factor: 2.649

Review 8.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Motohiro Yukitake; Eisaburo Sueoka; Naoko Sueoka-Aragane; Akemi Sato; Hiromi Ohashi; Yusuke Yakushiji; Mineki Saito; Mitsuhiro Osame; Shuji Izumo; Yasuo Kuroda
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

10.  Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells.

Authors:  Jaya Ahuja; Veronique Lepoutre; Brian Wigdahl; Zafar K Khan; Pooja Jain
Journal:  Biomed Pharmacother       Date:  2007-03-07       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.